c‐MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide‐dexamethasone in myeloma

OBJECTIVES: In the TOURMALINE‐MM1 phase 3 trial in relapsed/refractory multiple myeloma, ixazomib‐lenalidomide‐dexamethasone (IRd) showed different magnitudes of progression‐free survival (PFS) benefit vs placebo‐Rd according to number and type of prior therapies, with greater benefit seen in patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Bacco, Alessandra, Bahlis, Nizar J., Munshi, Nikhil C., Avet‐Loiseau, Hervé, Masszi, Tamás, Viterbo, Luísa, Pour, Ludek, Ganly, Peter, Cavo, Michele, Langer, Christian, Kumar, Shaji K., Rajkumar, S. Vincent, Keats, Jonathan J., Berg, Deborah, Lin, Jianchang, Li, Bin, Badola, Sunita, Shen, Lei, Zhang, Jacob, Esseltine, Dixie‐Lee, Luptakova, Katarina, van de Velde, Helgi, Richardson, Paul G., Moreau, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317705/
https://www.ncbi.nlm.nih.gov/pubmed/32145111
http://dx.doi.org/10.1111/ejh.13405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317705/
https://www.ncbi.nlm.nih.gov/pubmed/32145111
http://dx.doi.org/10.1111/ejh.13405

Ejemplares similares